Advanced Biomedical Instrumentation Centre (ABIC) cordially invite you to participate in the forthcoming symposium, titled “From Bench to Bedside: Symposium on Research Commercialization of Organoid-Based Innovations and Biomedical Instrumentation”, hosted by ABIC and co-organized by the Hong Kong Science and Technology Park. The event is collectively supported by BiomOrgan, C2i, C2i Tech, CVVT, GLOAS, HSITP and Invitrocue.

Date: Dec 2nd, 2023 (SAT)

Time: 1300-1730 (Registration: 1230)

Venue: Multi-function Room 2-3, Inno2, 2/F, Building 17W, Hong Kong Science Park

The symposium aims to bring together experts from diverse disciplines to discuss the challenges, opportunities, and strategies for effectively commercializing research related to organoid-based innovations and biomedical instrumentation. For instance, the FDA Modernization Act 2.0 recently legitimized that drugs thoroughly tested using either animal or non-animal models can proceed to clinical trials upon FDA approval. Furthermore, patient-derived organoids remain stable when grown outside the body, making them a valuable laboratory tool for ex vivo drug screening. The translation of these breakthroughs into commercial applications with impacts on clinical practice requires a concerted effort from researchers, industry professionals, and policymakers. The event will be structured as a crossover between academia and industries to explore trans-disciplinary business collaborations. Your valuable involvement will, therefore, substantially contribute further to the success of this collaborative effort.

Registration Link: https://shorturl.at/fmno6 (First come, first served)

For additional details, please refer to the registration link above and reserve your seat. Feel free to extend the invitation to relevant partners and collaborators in your network. Should you have any questions or require further information, please feel free to contact us at publicity@abic.hk or +852 3910 3956.

We look forward to welcoming your presence on this remarkable occasion.